Global HIV Vaccine Market Future Outlook 2015

May 19, 2015, 06:59 ET from Research and Markets

DUBLIN, May 19, 2015 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global HIV Vaccine Market Future Outlook"  report to their offering. 

     (Logo: )

Pharmaceutical companies have recognized the dearth of effective HIV medications due to which they are investing significant amount on research and development of HIV vaccines. Various candidates are at different stages of clinical trials and they would be introduced in market in coming years. Technology is developing at rapid rates due to which screening of selected candidate is expected to take place at lesser time. In this way, market winding times are expected to decrease due to lesser time in developmental phases. 

Manufacturing capabilities are highly developed but some tweaking has to be done according to HIV pathogen. Significant development in recombinant DNA technology and genetic engineering is also expected to accelerate the rate of HIV vaccine development. Investigators are also expected to find new modalities that will help in checking the AIDS. In this way, future of HIV vaccines market looks optimistic and it may be commercialized in next 5-10 years. 

"Global HIV Vaccine Market Future Outlook" Report Highlights: 

- Introduction to HIV Vaccines 
- Issues Related to the Development of HIV Vaccines 
- Parameters for Successful Commercialization of HIV Vaccines 
- Global HIV Vaccines Market Opportunity Analysis 
- Global HIV Vaccine Clinical Pipeline by Company & Phase 
- Global HIV Vaccine Clinical Pipeline: 100 Vaccines 
- Majority Vaccine in Preclinical Phase: 42 Vaccines 

Companies Mentioned 

- AlphaVax 
- Antigen Express 
- Argo Therapeutics 
- Bionor Pharmaceuticals 
- Celldex Therapeutics 
- FIT Biotech 
- Crucell Pharmaceutical 
- GeneCure 
- Genetic Immunity 
- GenVec 
- GeoVax Labs 
- Glaxo Smithkline 
- Immune Response BioPharma 
- Inovio Pharmaceuticals 
- Novartis 
- Oncolys Biopharma 
- PaxVax 
- Profectus Biosciences 
- Sanofi 
- TVAX Biomedical 

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

SOURCE Research and Markets